164 related articles for article (PubMed ID: 33123159)
1. T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.
Harris KM; Horn SE; Grant ML; Lang H; Sani G; Jensen-Wachspress MA; Kankate VV; Datar A; Lazarski CA; Bollard CM; Keller MD
Front Immunol; 2020; 11():575977. PubMed ID: 33123159
[TBL] [Abstract][Full Text] [Related]
2. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.
McLaughlin LP; Lang H; Williams E; Wright KE; Powell A; Cruz CR; Colberg-Poley AM; Barese C; Hanley PJ; Bollard CM; Keller MD
Cytotherapy; 2016 Dec; 18(12):1515-1524. PubMed ID: 27692559
[TBL] [Abstract][Full Text] [Related]
3. Mapping of an antigenic site on the nucleocapsid protein of human parainfluenza virus type 3.
Zvirbliene A; Sezaite I; Pleckaityte M; Kucinskaite-Kodze I; Juozapaitis M; Sasnauskas K
Viral Immunol; 2009 Jun; 22(3):181-8. PubMed ID: 19435414
[TBL] [Abstract][Full Text] [Related]
4. Genetic analyses of the fusion protein genes in human parainfluenza virus types 1 and 3 among patients with acute respiratory infections in Eastern Japan from 2011 to 2015.
Tsutsui R; Tsukagoshi H; Nagasawa K; Takahashi M; Matsushima Y; Ryo A; Kuroda M; Takami H; Kimura H
J Med Microbiol; 2017 Feb; 66(2):160-168. PubMed ID: 28266286
[TBL] [Abstract][Full Text] [Related]
5. Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3.
Fukushima K; Takahashi T; Ito S; Takaguchi M; Takano M; Kurebayashi Y; Oishi K; Minami A; Kato T; Park EY; Nishimura H; Takimoto T; Suzuki T
Virology; 2014 Sep; 464-465():424-431. PubMed ID: 25146600
[TBL] [Abstract][Full Text] [Related]
6. Protective antibodies against human parainfluenza virus type 3 infection.
Boonyaratanakornkit J; Singh S; Weidle C; Rodarte J; Bakthavatsalam R; Perkins J; Stewart-Jones GBE; Kwong PD; McGuire AT; Pancera M; Taylor JJ
MAbs; 2021; 13(1):1912884. PubMed ID: 33876699
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
8. Human parainfluenza virus type 1 regulates cholesterol biosynthesis and establishes quiescent infection in human airway cells.
Kurebayashi Y; Bajimaya S; Watanabe M; Lim N; Lutz M; Dunagan M; Takimoto T
PLoS Pathog; 2021 Sep; 17(9):e1009908. PubMed ID: 34529742
[TBL] [Abstract][Full Text] [Related]
9. The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo.
Lingemann M; Surman S; Amaro-Carambot E; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Mar; 89(6):3318-31. PubMed ID: 25589643
[TBL] [Abstract][Full Text] [Related]
10. Parainfluenza Virus Types 1, 2, and 3 in Pediatric Patients with Acute Respiratory Infections in Beijing During 2004 to 2012.
Wang F; Zhao LQ; Zhu RN; Deng J; Sun Y; Ding YX; Tian R; Qian Y
Chin Med J (Engl); 2015 Oct; 128(20):2726-30. PubMed ID: 26481737
[TBL] [Abstract][Full Text] [Related]
11. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
[TBL] [Abstract][Full Text] [Related]
12. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8
Wen J; Tang WW; Sheets N; Ellison J; Sette A; Kim K; Shresta S
Nat Microbiol; 2017 Mar; 2():17036. PubMed ID: 28288094
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells regulate T-cell proliferation during human parainfluenza virus type 3 infection.
Noone CM; Paget E; Lewis EA; Loetscher MR; Newman RW; Johnson PA
J Virol; 2008 Sep; 82(18):9299-302. PubMed ID: 18614637
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
[TBL] [Abstract][Full Text] [Related]
15. Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells.
Dave VP; Allan JE; Slobod KS; Smith FS; Ryan KW; Takimoto T; Power UF; Portner A; Hurwitz JL
Virology; 1994 Mar; 199(2):376-83. PubMed ID: 7510085
[TBL] [Abstract][Full Text] [Related]
16. Epitope specific T-cell responses against influenza A in a healthy population.
Savic M; Dembinski JL; Kim Y; Tunheim G; Cox RJ; Oftung F; Peters B; Mjaaland S
Immunology; 2016 Feb; 147(2):165-77. PubMed ID: 26489873
[TBL] [Abstract][Full Text] [Related]
17. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells.
Provenzano M; Mocellin S; Bettinotti M; Preuss J; Monsurrò V; Marincola FM; Stroncek D
J Immunother; 2002; 25(4):342-51. PubMed ID: 12142557
[TBL] [Abstract][Full Text] [Related]
19. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
20. Human parainfluenza virus type 3 inhibits gamma interferon-induced major histocompatibility complex class II expression directly and by inducing alpha/beta interferon.
Gao J; De BP; Han Y; Choudhary S; Ransohoff R; Banerjee AK
J Virol; 2001 Feb; 75(3):1124-31. PubMed ID: 11152485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
